Kehua Yuan1, Zhigang Chen2, Wenhui Li3, Chang E Gao4, Gaofeng Li5, Gang Guo5, Yi Yang3, Yiqin Ai3, Lu Wu3, Ming Zhang6. 1. Department of Oncology, Yan'an Hospital of Kunming City, Yan'an Hospital of Kunming Medical University, Kunming, China. 2. Department of Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China. 3. Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, China. 4. Department of Medical Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, China. 5. Department of Thoracic Surgery, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, China. 6. Department of Radiation Oncology, The Third Affiliated Hospital of Kunming Medical University, Tumor Hospital of Yunnan Province, Kunming, China. Electronic address: kmzhming@163.com.
Abstract
BACKGROUND AND AIMS: Midkine (MDK) is a heparin-binding growth factor and is overexpressed in various types of human cancer. However, little is known about the clinical significance of MDK in non-small cell lung cancer (NSCLC). The aim of this study was to measure MDK protein levels in patients with NSCLC and to explore its clinical significance. METHODS: The expression status of MDK in NSCLC at Gene Expression Omnibus (GEO accession number: GSE19804) was observed. The expression of MDK mRNA and protein was examined in NSCLC tissues and normal lung tissues through real-time PCR and Western blot. Meanwhile, the relationship of MDK protein expression levels with clinical characteristics of 186 NSCLC patients was analyzed by immunohistochemistry. RESULTS: MDK expression was increased in NSCLC tissues compared with paired normal lung tissues in microarray data (GSE19804). MDK mRNA and protein expression were obviously increased in NSCLC tissues than in paired adjacent normal lung tissues. Using immunohistochemistry, MDK protein overexpression was positively correlated with status of clinical stage, T classification, N classification, and M classification in NSCLC patients. In survival analysis, patients with higher MDK protein expression had a significantly shorter overall survival time than did patients with lower MDK protein expression. Multivariate analysis indicated that the MDK protein overexpression was an independent poor prognostic indicator for patients with NSCLC. CONCLUSIONS: MDK plays an important role in NSCLC progression and prognosis and may act as a convincing prognostic indicator for NSCLC patients.
BACKGROUND AND AIMS: Midkine (MDK) is a heparin-binding growth factor and is overexpressed in various types of humancancer. However, little is known about the clinical significance of MDK in non-small cell lung cancer (NSCLC). The aim of this study was to measure MDK protein levels in patients with NSCLC and to explore its clinical significance. METHODS: The expression status of MDK in NSCLC at Gene Expression Omnibus (GEO accession number: GSE19804) was observed. The expression of MDK mRNA and protein was examined in NSCLC tissues and normal lung tissues through real-time PCR and Western blot. Meanwhile, the relationship of MDK protein expression levels with clinical characteristics of 186 NSCLCpatients was analyzed by immunohistochemistry. RESULTS:MDK expression was increased in NSCLC tissues compared with paired normal lung tissues in microarray data (GSE19804). MDK mRNA and protein expression were obviously increased in NSCLC tissues than in paired adjacent normal lung tissues. Using immunohistochemistry, MDK protein overexpression was positively correlated with status of clinical stage, T classification, N classification, and M classification in NSCLCpatients. In survival analysis, patients with higher MDK protein expression had a significantly shorter overall survival time than did patients with lower MDK protein expression. Multivariate analysis indicated that the MDK protein overexpression was an independent poor prognostic indicator for patients with NSCLC. CONCLUSIONS:MDK plays an important role in NSCLC progression and prognosis and may act as a convincing prognostic indicator for NSCLCpatients.
Authors: Dezső Módos; Krishna C Bulusu; Dávid Fazekas; János Kubisch; Johanne Brooks; István Marczell; Péter M Szabó; Tibor Vellai; Péter Csermely; Katalin Lenti; Andreas Bender; Tamás Korcsmáros Journal: NPJ Syst Biol Appl Date: 2017-01-24
Authors: Tamina Rawnaq-Möllers; Tarik Ghadban; Louisa Stern; Erik Mueller; Eugen Bellon; Matthias Reeh; Rainer Grotelueschen; Cenap Guengoer; Nathaniel Melling; Mara Goetz; Daniel R Perez; Jakob R Izbicki Journal: Sci Rep Date: 2021-07-16 Impact factor: 4.379